HOOK Insider Trading
Insider Ownership Percentage: 3.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $39,362.20
HOOKIPA Pharma Share Price & Price History
Current Price: $0.89
Price Change: ▲ Price Increase of +0.0263 (3.06%)
As of 12/4/2025 02:51 PM ET
HOOKIPA Pharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/22/2025 | Malte Peters | CEO | Sell | 29,176 | $0.92 | $26,841.92 | 79,519 | |
| 7/22/2025 | Mary Theresa Coelho | CFO | Sell | 13,609 | $0.92 | $12,520.28 | 56,266 | |
| 8/21/2023 | Reinhard Kandera | CFO | Buy | 700 | $7.20 | $5,040.00 | 4,309 | |
| 8/16/2023 | Reinhard Kandera | CFO | Buy | 800 | $7.10 | $5,680.00 | 3,609 | |
| 7/11/2023 | Jorn Aldag | CEO | Buy | 500 | $8.30 | $4,150.00 | 7,195 | |
| 7/7/2023 | Jorn Aldag | CEO | Buy | 500 | $8.10 | $4,050.00 | 6,695 | |
| 7/5/2023 | Jorn Aldag | CEO | Buy | 500 | $8.90 | $4,450.00 | 6,195 | |
| 7/3/2023 | Jorn Aldag | CEO | Buy | 500 | $8.90 | $4,450.00 | 5,695 | |
| 6/30/2023 | Reinhard Kandera | CFO | Buy | 1,200 | $8.80 | $10,560.00 | 2,809 | |
HOOKIPA Pharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/17/2025 | Squarepoint Ops LLC | 51,960 | $0.10M | 0.0% | N/A | 0.431% |  |
| 2/17/2025 | Millennium Management LLC | 15,326 | $31K | 0.0% | N/A | 0.127% |  |
| 2/14/2025 | Gilead Sciences Inc. | 1,875,945 | $3.77M | 0.2% | N/A | 15.555% |  |
| 11/16/2024 | Geode Capital Management LLC | 72,679 | $0.31M | 0.0% | -89.7% | 0.603% |  |
| 11/15/2024 | State Street Corp | 16,967 | $73K | 0.0% | -90.0% | 0.141% |  |
| 11/15/2024 | Redmile Group LLC | 106,376 | $0.46M | 0.0% | -90.0% | 0.882% |  |
| 11/15/2024 | Ikarian Capital LLC | 53,076 | $0.23M | 0.0% | N/A | 0.440% |  |
| 11/15/2024 | Baker BROS. Advisors LP | 812,814 | $3.50M | 0.0% | -90.0% | 6.740% |  |
| 11/14/2024 | Knoll Capital Management LLC | 551,738 | $2.37M | 1.2% | -90.0% | 4.577% |  |
| 11/13/2024 | FMR LLC | 341,476 | $1.47M | 0.0% | -90.0% | 2.831% |  |
| 11/5/2024 | GSA Capital Partners LLP | 16,609 | $71K | 0.0% | -86.1% | 0.138% |  |
| 8/9/2024 | Renaissance Technologies LLC | 302,246 | $0.18M | 0.0% | +38.4% | 3.055% |  |
| 8/6/2024 | Acadian Asset Management LLC | 991,106 | $0.59M | 0.0% | +12.3% | 10.011% |  |
| 5/20/2024 | Virtu Financial LLC | 43,021 | $31K | 0.0% | N/A | 0.043% |  |
| 5/10/2024 | Acadian Asset Management LLC | 882,262 | $0.63M | 0.0% | +85.8% | 0.892% |  |
| 11/15/2023 | Redmile Group LLC | 1,063,769 | $0.66M | 0.0% | -67.7% | 1.267% |  |
| 11/15/2023 | Armistice Capital LLC | 3,712,000 | $2.29M | 0.0% | -3.7% | 4.422% |  |
| 8/22/2023 | CHI Advisors LLC | 788,740 | $0.69M | 0.2% | N/A | 1.441% |  |
| 8/11/2023 | Artal Group S.A. | 5,666,410 | $4.99M | 0.2% | +206.4% | 10.355% |  |
| 8/7/2023 | Acadian Asset Management LLC | 428,353 | $0.38M | 0.0% | -37.2% | 0.783% |  |
| 8/4/2023 | Maven Securities LTD | 146,037 | $0.13M | 0.0% | N/A | 0.267% |  |
| 7/24/2023 | Vontobel Holding Ltd. | 45,000 | $40K | 0.0% | N/A | 0.082% |  |
| 5/11/2023 | Acadian Asset Management LLC | 682,349 | $0.50M | 0.0% | +6.0% | 1.247% |  |
| 5/1/2023 | Virtu Financial LLC | 62,308 | $46K | 0.0% | N/A | 0.114% |  |
| 2/14/2023 | Susquehanna International Group LLP | 45,014 | $36K | 0.0% | +99.5% | 0.082% |  |
| 2/14/2023 | EcoR1 Capital LLC | 2,473,489 | $2M | 0.1% | -50.5% | 4.521% |  |
| 11/10/2022 | Connor Clark & Lunn Investment Management Ltd. | 22,102 | $30K | 0.0% | N/A | 0.040% |  |
| 11/7/2022 | Virtu Financial LLC | 43,507 | $58K | 0.0% | +50.9% | 0.080% |  |
| 5/16/2022 | Deep Track Capital LP | 5,035,998 | $11.48M | 0.7% | N/A | 9.209% |  |
| 5/12/2022 | Artal Group S.A. | 1,849,616 | $4.22M | 0.2% | +208.5% | 3.382% |  |
| 5/11/2022 | GSA Capital Partners LLP | 77,878 | $0.18M | 0.0% | +124.2% | 0.142% |  |
| 5/9/2022 | Banque Cantonale Vaudoise | 20,000 | $46K | 0.0% | N/A | 0.037% |  |
| 2/14/2022 | Redmile Group LLC | 2,385,136 | $5.56M | 0.1% | +29.3% | 9.125% |  |
| 2/14/2022 | GSA Capital Partners LLP | 34,734 | $81K | 0.0% | N/A | 0.133% |  |
| 2/10/2022 | Acadian Asset Management LLC | 252,256 | $0.59M | 0.0% | +210.5% | 0.965% |  |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 39,715 | $92K | 0.0% | N/A | 0.152% |  |
| 12/14/2021 | UBS Asset Management Americas Inc. | 320,400 | $1.89M | 0.0% | -3.3% | 1.226% |  |
| 11/16/2021 | Two Sigma Advisers LP | 85,600 | $0.50M | 0.0% | +631.6% | 0.328% |  |
| 11/16/2021 | Two Sigma Investments LP | 186,356 | $1.10M | 0.0% | +495.0% | 0.715% |  |
| 11/15/2021 | HighVista Strategies LLC | 12,051 | $71K | 0.0% | N/A | 0.046% |  |
| 11/12/2021 | Geode Capital Management LLC | 405,421 | $2.39M | 0.0% | +6.8% | 1.555% |  |
| 11/12/2021 | Connor Clark & Lunn Investment Management Ltd. | 12,869 | $76K | 0.0% | N/A | 0.049% |  |
| 11/9/2021 | Barclays PLC | 16,368 | $96K | 0.0% | +573.9% | 0.063% |  |
| 11/9/2021 | BlackRock Inc. | 1,053,514 | $6.20M | 0.0% | +0.3% | 4.041% |  |
| 11/8/2021 | Los Angeles Capital Management LLC | 50,591 | $0.30M | 0.0% | +35.2% | 0.194% |  |
| 11/5/2021 | Advisory Services Network LLC | 11,800 | $70K | 0.0% | N/A | 0.045% |  |
| 8/16/2021 | Royal Bank of Canada | 35,858 | $0.33M | 0.0% | +200.3% | 0.138% |  |
| 8/16/2021 | Goldman Sachs Group Inc. | 34,526 | $0.32M | 0.0% | -80.2% | 0.133% |  |
Data available starting January 2016
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More on HOOKIPA Pharma
Volume
19,010 shs
Average Volume
94,460 shs
Market Capitalization
$10.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91
Who are the company insiders with the largest holdings of HOOKIPA Pharma?